ICCC Q4 2019 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+23.7% YoY

Gross Profit

$2M50.6% margin

Operating Income

-$242,465-6.7% margin

Net Income

-$310,451-8.5% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+22.3%

Cash Flow

Operating Cash Flow

-$46,622

Free Cash Flow

-$738,051

Stock-Based Comp.

$91,575

Balance Sheet

Total Assets

$39M

Total Liabilities

$10M

Stockholders' Equity

$29M

Cash & Equivalents

$6M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$3M	+23.7%
Gross Profit	$2M	$1M	+31.7%
Operating Income	-$242,465	-$926,000	+73.8%
Net Income	-$310,451	-$1M	+70.5%